Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function. We’re seeing success across a range of soluble and hard-to-drug membrane proteins including a Claudin and a GPCR. We’ve extensively tested these designs in our wet lab and included detailed data and controls, providing the first clear demonstration of how de novo design could expand the scope and efficiency of therapeutic antibody discovery. 🧵 Technical report: nabla-public.s3.us-east-1.am… Blog: nabla.bio/news/denovo

I’m speaking today at @PEGSboston, 5:10 pm, Eng Antibodies. Talk will cover new “solMPMP” tech from @nablabio where we use generative ML to create soluble proxies of valuable multipass membrane protein drug targets, and use these proxies to facilitate design of new biologics.